Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. [electronic resource]
Producer: 20071213Description: 1242-8 p. digitalISSN:- 1551-4005
- Animals
- Boronic Acids -- pharmacology
- Bortezomib
- Dipeptides -- pharmacology
- Dystrophin -- metabolism
- Dystrophin-Associated Proteins -- metabolism
- Male
- Mice
- Mice, Inbred mdx
- Microscopy, Fluorescence
- Muscle, Skeletal -- metabolism
- Muscular Dystrophy, Duchenne -- drug therapy
- NF-kappa B -- metabolism
- Protease Inhibitors -- pharmacology
- Pyrazines -- pharmacology
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.